Patients with acromegaly face increased risks for overall cancer, lung and hematologic malignancies, and all-cause mortality.

The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.

A nine-protein APOL1 Proteomic Risk Score (APRS) enables accurate prediction of kidney disease progression in APOL1 high-risk individuals.

Hispanic patients exhibit higher thyroid malignancy rates than non-Hispanic patients despite similar TI-RADS and Bethesda scores.

Burosumab treatment is associated with improved long-term growth outcomes in children and adolescents with X-linked hypophosphatemia.

An umbrella review in JAMA Network Open finds low credibility for most noncardiometabolic effects of GLP-1RAs in clinical studies.

Baseline osteoporosis and axial disease predicted higher odds of needing to switch therapies in pediatric chronic nonbacterial osteomyelitis.

Higher intake of cereal- and fruit-based fiber is associated with a significantly lower risk for T2D and improved metabolic biomarkers.

For adults with T2D, a ketogenic diet (KD) reduces the proportion of proinsulin secreted to a greater extent than a low-fat diet (LFD).

Treatment with a once-daily pill containing three low-dose antihypertensive agents is associated with a lower incidence of recurrent stroke.

Phase 2/3 trial data show VDPHL01, an oral non-hormonal extended-release minoxidil, improves hair growth and patient-reported outcomes in male pattern hair loss.

IVF-dated ultrasound criteria, including absence of fetal cardiac activity at 45 days, support earlier, accurate pregnancy loss diagnosis.